American Society of Hematology

Figure 3

$Figure 3. Functional analysis in the NOD/SCID repopulating ATL-like lymphoma cells. (A) SP cell analysis in the NOD/SCID repopulating ATL-like lymphoma cells. The SP regions are indicated by a trapezoid on each panel. (Left panel) Approximately 0.064% of SP cells were observed in the SLCs. (Right panel) SP cell analysis after treatment with verapamil (100 μM), where the SP fraction was lost. (B) Triple-staining analysis of CD38, CD71, and CD117 in the SP fraction. More than 50% of CD38−/CD71−/CD117+ corresponded to the SP fraction. (C) FACS CD38−/CD71−/CD117+ and CD38−/CD71−/CD117− cells. (D) Cytospin analysis of the CSC candidate (CD38−/CD71−/CD117+) and (E) non-CSC candidate (CD38+/CD71+/CD117−) populations.$

Functional analysis in the NOD/SCID repopulating ATL-like lymphoma cells. (A) SP cell analysis in the NOD/SCID repopulating ATL-like lymphoma cells. The SP regions are indicated by a trapezoid on each panel. (Left panel) Approximately 0.064% of SP cells were observed in the SLCs. (Right panel) SP cell analysis after treatment with verapamil (100 μM), where the SP fraction was lost. (B) Triple-staining analysis of CD38, CD71, and CD117 in the SP fraction. More than 50% of CD38⁻/CD71⁻/CD117⁺ corresponded to the SP fraction. (C) FACS CD38⁻/CD71⁻/CD117⁺ and CD38⁻/CD71⁻/CD117⁻ cells. (D) Cytospin analysis of the CSC candidate (CD38⁻/CD71⁻/CD117⁺) and (E) non-CSC candidate (CD38⁺/CD71⁺/CD117⁻) populations.

This Feature Is Available To Subscribers Only